Bisphosphonates and other bone agents for breast cancer-Reference-Cited by-同舟云学术

Bisphosphonates and other bone agents for breast cancer

Published:2017-10-30 Issue:11 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

O'Carrigan Brent¹²,Wong Matthew HF³,Willson Melina L⁴,Stockler Martin R⁵,Pavlakis Nick⁶,Goodwin Annabel⁷⁸⁹

Affiliation:

1. Chris O'Brien Lifehouse; Medical Oncology; 119-143 Missenden Rd Camperdown Sydney NSW UK 2050

2. The University of Sydney; Camperdown Australia

3. Gosford Hospital; Department of Medical Oncology; Gosford New South Wales Australia

4. NHMRC Clinical Trials Centre, The University of Sydney; Systematic Reviews and Health Technology Assessments; Locked Bag 77 Sydney NSW Australia 1450

5. The University of Sydney; NHMRC Clinical Trials Centre and Sydney Cancer Centre; GH6 RPAH Missenden Road Camperdown NSW Australia 2050

6. Royal North Shore Hospital; Department of Medical Oncology; Pacific Highway St Leonards New South Wales Australia 2065

7. The University of Sydney, Concord Repatriation General Hospital; Concord Clinical School; Concord NSW Australia 2137

8. Concord Repatriation General Hospital; Medical Oncology Department; Concord Australia

9. Sydney Local Health District and South Western Sydney Local Health District; Cancer Genetics Department; Sydney Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003474.pub4/epdf/full

Reference252 articles.

1. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer;Gnant;Cancer Research,2011

2. Endocrine therapy plus zoledronic acid in premenopausal breast cancer;Gnant;New England Journal of Medicine,2009

3. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial;Gnant;Lancet Oncology,2011

4. Gnant M Mlineritsch B Stoeger H Luschin-Ebengreuth G Knauer M Moik M Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Annals of Oncology 2015 313 20

5. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer;Gnant;Journal of Clinical Oncology,2010

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Remineralization of lytic spinal metastases after radiation therapy – A retrospective cohort study comparing conventional external beam radiation therapy with stereotactic ablative body radiation;Clinical and Translational Radiation Oncology;2024-09

2. Urinary biomarkers in metastatic bone pain: Results from a multicentre randomized trial of ibandronate compared to single dose radiotherapy for localized metastatic bone pain in prostate cancer (RIB);Journal of Bone Oncology;2024-08

3. A multifaceted role of bisphosphonates from palliative care to anti-cancer therapy in solid tumors;Journal of Oncology Pharmacy Practice;2024-07-26

4. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-07-09

5. Antiresorptive agents enhance ossification of free flap reconstructions of the mandible: a radiological retrospective cohort study;Frontiers in Oncology;2024-06-12